Current status of vaccines in psychiatry—A narrative review

Asian Journal of Psychiatry

Volumn 31, Issue , 2018, Pages 112-120

  Kuppili, Pooja Patnaik ^a   Manohar, Harshini ^a   Menon, Vikas ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Alzheimer's Dementia; Autism; Psychiatry; Substance use disorder; Vaccines

Indexed keywords

ALZHEIMER DISEASE VACCINE; MEASLES MUMPS RUBELLA VACCINE; VANUTIDE CRIDIFICAR; IMMUNOLOGIC FACTOR; VACCINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; AUTISM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOREACTIVITY; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SYSTEMATIC REVIEW; VACCINATION; IMMUNOLOGY; MENTAL DISEASE;

HUMANS; IMMUNOLOGIC FACTORS; MENTAL DISORDERS; VACCINATION; VACCINES;

EID: 85042214491     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2018.02.004     Document Type: Review

References (74)

1. Akbarzadeh, A., Norouzian, D., Farhangi, A., et al. Immunotherapy of 347 volunteer outpatient morphine addicts by human therapeutic morphine vaccine in Kermanshah province of Iran. J. Pharmacol. Toxicol. 4 (2009), 30–35.
2. Alving, C.R., Matyas, G.R., Torres, O., Jalah, R., Beck, Z., Adjuvants for vaccines to drugs of abuse and addiction. Vaccine 32 (2014), 5382–5389.
3. Confirmed cases of measles, mumps and rubella in England and Wales: 1996 to 2016 − GOV.UK [WWW Document], 2014. URL https://www.gov.uk/government/publications/measles-confirmed-cases/confirmed-cases-of-measles-mumps-and-rubella-in-england-and-wales-2012-to-2013 (Accessed 24 May 2017).
4. Arai, H., Suzuki, H., Yoshiyama, T., Vanutide Cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr. Alzheimer Res. 12 (2015), 242–254.
5. Bayer, A.J., Bullock, R., Jones, R.W., Wilkinson, D., Paterson, K.R., Jenkins, L., Millais, S.B., Donoghue, S., Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64 (2005), 94–101.
6. Bevins, R.A., Wilkinson, J.L., Sanderson, S.D., Vaccines to combat smoking. Expert Opin. Biol. Ther. 8 (2008), 379–383.
7. Bonese, K.F., Wainer, B.H., Fitch, F.W., Rothberg, R.M., Schuster, C.R., Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252 (1974), 708–710.
8. Brogan, K., Psychobiology of vaccination effects: bidirectional relevance of depression. Altern. Ther. Health Med., 21, 2015, 18.
9. Brown, K.F., Long, S.J., Ramsay, M., Hudson, M.J., Green, J., Vincent, C.A., Kroll, J.S., Fraser, G., Sevdalis, N., UK parents’ decision-making about measles-mumps-rubella (MMR) vaccine 10 years after the MMR-autism controversy: a qualitative analysis. Vaccine 30 (2012), 1855–1864, 10.1016/j.vaccine.2011.12.127.
10. Cornuz, J., Zwahlen, S., Jungi, W.F., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One, 3, 2008, 2547.
11. Dales, L., Hammer, S.J., Smith, N.J., Time trends in Autism and in MMR immunization coverage in California. JAMA 285 (2001), 1183–1185, 10.1001/jama.285.9.1183.
12. Dally, A., The rise and fall of pink disease. Soc. Hist. Med. 10 (1997), 291–304.
13. Deer, B., Wakefield's autistic enterocolitis under the microscope. BMJ, 340, 2010, c1127.
14. Dols, A., Van den Brink, W., Eikelenboom, P., Vaccinations in psychiatry. Tijd. voor Psychiatr. 51 (2009), 751–759.
15. Eggertson, L., Lancet retracts 12-year-old article linking autism to MMR vaccines. Can. Med. Assoc. J. 182 (2010), E199–E200, 10.1503/cmaj.109-3179.
16. Esterlis, I., Hannestad, J.O., Perkins, E., et al. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am. J. Psychiatry 170 (2013), 399–407.
17. Farhangi, A., Akbarzadeh, A., Mehrabi, M., et al. Immunotherapy of 436 morphine addicts by therapeutic morphine vaccine in Kerman province (IR Iran). J. Vaccin Vaccin., 2, 2012, 117.
18. Farrington, C.P., Miller, E., Taylor, B., MMR and autism: further evidence against a causal association. Vaccine 19 (2001), 3632–3635.
19. Fettelschoss, A., Zabel, F., Bachmann, M.F., Vaccination against Alzheimer disease: an update on future strategies. Hum. Vaccines Immunother. 10 (2014), 847–851.
20. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F., others, Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005), 1553–1562.
21. Godlee, F., Smith, J., Marcovitch, H., Wakefield's article linking MMR vaccine and autism was fraudulent. BMJ, 342, 2011, c7452, 10.1136/bmj.c7452.
22. Goniewicz, M.L., Delijewski, M., Nicotine vaccines to treat tobacco dependence. Hum. Vaccines Immunother. 9 (2013), 13–25.
23. Hüll, M., Sadowsky, C., Arai, H., Le Prince, L., Holstein, A., Booth, K., Peng, Y., Yoshiyama, T., Suzuki, H., Ketter, N., Liu, E., Long-term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate Alzheimer's disease. Curr. Alzheimer Res. 14:7 (2017), 696–708.
24. Haney, M., Kosten, T.R., Therapeutic vaccines for substance dependence. Expert Rev. Vaccines 3 (2004), 11–18.
25. Haney, M., Gunderson, E.W., Jiang, H., Collins, E.D., Foltin, R.W., Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 67 (2010), 59–65.
26. Hatsukami, D.K., Rennard, S., Jorenby, D., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 78 (2005), 456–467.
27. Hatsukami, D.K., Jorenby, D.E., Gonzales, D., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 89 (2011), 392–399.
28. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Bullock, R., Love, S., Neal, J.W., others, Long-term effects of Aβ 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008), 216–223.
29. Honda, H., Shimizu, Y., Rutter, M., No effect of MMR withdrawal on the incidence of autism: a total population study. J. Child Psychol. Psychiatry 46 (2005), 572–579.
30. Hoogsteder, P.H., Kotz, D., Spiegel, P.I., Viechtbauer, W., Schayck, O.C., Efficacy of the nicotine vaccine 3′-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction 109 (2014), 1252–1259.
31. Jain, R., Juneja, M., Sairam, S., Children with developmental disabilities in India: age of initial concern and referral for rehabilitation services, and reasons for delay in referral. J. Child Neurol. 28 (2013), 455–460, 10.1177/0883073812447685.
32. Kawashima, H., Mori, T., Kashiwagi, Y., Takekuma, K., Hoshika, A., Wakefield, A., Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig. Dis. Sci. 45 (2000), 723–729.
33. Kemper, T.L., Bauman, M.L., Neuropathology of infantile autism. Mol. Psychiatry, 7, 2002, S12.
34. Kim, H.-J., Jeon, S.-W., Yoon, H.-K., Recurrence of panic attacks after influenza vaccination: two case reports. Clin. Psychopharmacol. Neurosci., 14, 2016, 396.
35. Kinsey, B., Vaccines against drugs of abuse: where are we now?. Ther. Adv. Vaccines 2 (2014), 106–117.
36. Kondo, K., Congenital Minamata disease: warnings from Japan's experience. J. Child Neurol. 15 (2000), 458–464.
37. Kosten, T., Owens, S.M., Immunotherapy for the treatment of drug abuse. Pharmacol. Ther. 108 (2005), 76–85.
38. Kosten, T.R., Rosen, M., Bond, J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20 (2002), 1196–1204.
39. Kosten, T.R., Domingo, C.B., Hamon, S.C., Nielsen, D.A., DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci. Lett. 541 (2013), 29–33.
40. Kosten, T., Domingo, C., Orson, F., Kinsey, B., Vaccines against stimulants: cocaine and MA. Br. J. Clin. Pharmacol. 77 (2014), 368–374.
41. Leader, A.E., Lerman, C., Cappella, J.N., Nicotine vaccines: will smokers take a shot at quitting?. Nicotine Tob. Res., 2010, ntq015.
42. Lemere, C.A., Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol. Neurodegener., 8, 2013, 36.
43. Leslie, D.L., Kobre, R.A., Richmand, B.J., Guloksuz, S.A., Leckman, J.F., Temporal association of certain neuropsychiatric Disorders Following Vaccination of children and adolescents: a Pilot case–control study. Front. Psychiatry, 2017, 8.
44. Madsen, K.M., Lauritsen, M.B., Pedersen, C.B., Thorsen, P., Plesner, A.-M., Andersen, P.H., Mortensen, P.B., Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 112 (2003), 604–606.
45. Martell, B.A., Orson, F.M., Poling, J., et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 66 (2009), 1116–1123.
46. Mathers, C., Fat, D.M., Boerma, J.T., The Global Burden of Disease: 2004 Update. 2008, World Health Organization.
47. Maurer, P., Jennings, G.T., Willers, J., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. Eur. J. Immunol. 35 (2005), 2031–2040.
48. Modabbernia, A., Velthorst, E., Reichenberg, A., Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. Mol. Autism, 8, 2017, 13.
49. Monsonego, A., Weiner, H.L., Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003), 834–838.
50. Müller, N., Myint, A.M., Schwarz, M.J., (eds.) Immunology and Psychiatry: From Basic Research to Therapeutic Interventions, vol. 8, 2015, Springer.
51. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O., Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9 (2003), 448–452.
52. Nicoll, J.A., Barton, E., Boche, D., Neal, J.W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., others, Aβ species removal after Aβ42 immunization. J. Neuropathol. Exp. Neurol. 65 (2006), 1040–1048.
53. Nielsen, D.A., Hamon, S.C., Kosten, T.R., κ-Opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr. Genet. 23 (2013), 225–232.
54. Novak, P., Schmidt, R., Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., Vince-Kazmerova, Z., Katina, S., Fialova, L., Prcina, M., others, Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16 (2017), 123–134.
55. Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., others, Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61 (2003), 46–54.
56. Orson, F.M., Kinsey, B.M., Singh, R.A., Wu, Y., Gardner, T., Kosten, T.R., Substance abuse vaccines. Ann. N. Y. Acad. Sci. 1141 (2008), 257–269.
57. Parker, S.K., Schwartz, B., Todd, J., Pickering, L.K., Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 114 (2004), 793–804.
58. Pasquier, F., Sadowsky, C., Holstein, A., Leterme, G.L.P., Peng, Y., Jackson, N., Fox, N.C., Ketter, N., Liu, E., Ryan, J.M., Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer's disease. J. Alzheimers Dis. 51 (2016), 1131–1143.
59. Pentel, P.R., LeSage, M.G., New directions in nicotine vaccine design and use. Adv. Pharmacol., 69, 2014, 553 San Diego, Calif.
60. Pichichero, M.E., Cernichiari, E., Lopreiato, J., Treanor, J., Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 360 (2002), 1737–1741.
61. Plotkin, S., Gerber, J.S., Offit, P.A., Vaccines and autism: a tale of shifting hypotheses. Clin. Infect. Dis. 48 (2009), 456–461.
62. Pravetoni, M., Biologics to treat substance use disorders: current status and new directions. Hum. Vaccines Immunother. 12 (2016), 3005–3019.
63. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.-Q., Mucke, L., Reducing endogenous tau ameliorates amyloid s s-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007), 750–754.
64. Robinson, S.R., Bishop, G.M., Lee, H., Münch, G., Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging 25 (2004), 609–615.
65. Rutter, M., Incidence of autism spectrum disorders: changes over time and their meaning*. Acta Paediatr. 94 (2005), 2–15, 10.1111/j.1651-2227.2005.tb01779.x.
66. Sigurdsson, E.M., Wisniewski, T., Frangione, B., A safer vaccine for Alzheimer's disease?. Neurobiol. Aging 23 (2002), 1001–1008.
67. Taylor, B., Miller, E., Lingam, R., Andrews, N., Simmons, A., Stowe, J., Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 324 (2002), 393–396.
68. ®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob. Res. 15 (2013), 1492–1501.
69. Wakefield, A., Murch, S., Anthony, A., Linnell, J., Casson, D., Malik, M., Berelowitz, M., Dhillon, A., Thomson, M., Harvey, P., Valentine, A., Davies, S., Walker-Smith, J., RETRACTED: ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351 (1998), 637–641, 10.1016/S0140-6736(97)11096-0.
70. Winblad, B., Andreasen, N., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., Maguire, R.P., Blennow, K., Lundmark, J., Staufenbiel, M., others, Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 11 (2012), 597–604.
71. Winblad, B., Graf, A., Riviere, M.-E., Andreasen, N., Ryan, J.M., Active immunotherapy options for Alzheimer's disease. Alzheimers Res. Ther., 6, 2014, 7.
72. Wing, L., Potter, D., The epidemiology of autistic spectrum disorders: is the prevalence rising?. Dev. Disabil. Res. Rev. 8 (2002), 151–161.
73. Wisniewski, T., Goñi, F., Immunotherapeutic approaches for Alzheimer's disease. Neuron 85 (2015), 1162–1176.
74. Yoshimasu, K., Kiyohara, C., Takemura, S., Nakai, K., A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood. Neurotoxicology 44 (2014), 121–131.